Recombinant Mycoplasma pneumoniae Phenylalanine--tRNA ligase alpha subunit (pheS)

Basic Research Questions

• What is Phenylalanine-tRNA ligase alpha subunit (pheS) in Mycoplasma pneumoniae and how does it function?

The pheS protein constitutes the alpha subunit of Phenylalanine-tRNA synthetase (PheRS) in M. pneumoniae, a critical enzyme in protein synthesis that catalyzes the attachment of phenylalanine to its cognate tRNA. Similar to other bacterial PheRS enzymes, it likely functions as part of a heterotetramic (α₂β₂) structure, with the alpha subunit containing the adenylation domain responsible for activating phenylalanine with ATP.

Based on structural characterization of related bacterial phenylalanine-tRNA synthetases, the active site of the pheS adenylation domain contains specific subpockets dedicated to recognition of L-phenylalanine and ATP substrates . The enzyme catalyzes a two-step reaction:

• Activation: Phenylalanine + ATP → Phenylalanyl-adenylate + PPi

• Transfer: Phenylalanyl-adenylate + tRNAPhe → Phenylalanyl-tRNAPhe + AMP

This aminoacylation function is essential for accurate protein synthesis in M. pneumoniae, which is the causative agent of atypical pneumonia and other respiratory tract infections .

• What challenges exist in expressing recombinant Mycoplasma pneumoniae proteins?

The primary challenge when expressing M. pneumoniae proteins in heterologous systems is the organism's unusual codon usage, particularly its use of the UGA codon to encode tryptophan rather than as a stop codon. When M. pneumoniae genes containing UGA codons are expressed in standard E. coli systems, premature termination occurs, resulting in truncated, non-functional proteins .

This phenomenon has been specifically documented with M. pneumoniae adhesin proteins: "A major limitation in developing a specific diagnostic test for M. pneumoniae is the inability to express adhesin proteins in heterologous expression systems due to unusual usage of the UGA stop codon, leading to premature termination of these proteins in Escherichia coli" .

Additional challenges include:

• Maintaining proper protein folding in heterologous systems

• Achieving sufficient protein yield for structural and functional studies

• Preserving enzymatic activity during purification processes

• Optimizing expression conditions for potentially toxic proteins

• What expression systems and purification strategies are most effective for recombinant M. pneumoniae pheS?

While the search results don't specifically address pheS expression, effective strategies can be inferred from successful expression of other M. pneumoniae proteins:

Expression systems:

• Modified E. coli strains containing tRNA suppressors for UGA codons

• Codon-optimized synthetic genes with UGA→UGG substitutions

• Cell-free protein synthesis systems with supplemented components

• Expression of protein fragments that avoid problematic UGA codons

Purification approaches:

• Affinity chromatography using His-tag fusion proteins (as seen with M. pneumoniae P1 protein fragments)

• Sequential chromatographic steps: ion exchange followed by size exclusion

• Typical buffer systems containing protease inhibitors (e.g., 1 mM PMSF) and stabilizing agents

A representative purification protocol based on related proteins would include:

• Cell lysis in buffer containing protease inhibitors (e.g., "50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF and 1% NP-40")

• Clarification by centrifugation

• Affinity purification using Ni-NTA or similar resin for His-tagged proteins

• SDS-PAGE analysis to confirm purity

• Western blotting validation using tag-specific antibodies

• How does the structure of M. pneumoniae pheS compare with other bacterial phenylalanine-tRNA synthetases?

While specific structural data for M. pneumoniae pheS is not presented in the search results, important insights can be drawn from the high-resolution structures of the related Mycobacterium tuberculosis Phe-tRNA synthetase (MtFRS) .

Key structural features likely to be conserved in M. pneumoniae pheS:

• An adenylation domain containing binding sites for both L-phenylalanine and ATP

• A protein gate controlling access to the active site, which regulates substrate entry and product release

• Specific tRNA recognition elements that enable accurate selection of tRNAPhe

The interaction with tRNA occurs in two distinct stages:

• "Initial tRNA recognition" state - involving indirect readout of the anticodon stem-loop

• "Aminoacylation ready" state - positioning the 3' end of tRNAPhe for accepting the activated amino acid

Researchers should anticipate both conserved catalytic residues and species-specific features that might reflect adaptation to M. pneumoniae's minimal genome and parasitic lifestyle.

Advanced Research Questions

• What methodological approaches are recommended for studying enzymatic activity of recombinant M. pneumoniae pheS?

Several complementary approaches can be employed to characterize pheS enzymatic activity:

Aminoacylation assays:

• Radioactive assays tracking [³H]-phenylalanine or [³²P]-tRNA incorporation

• HPLC-based methods to separate charged from uncharged tRNAs

• Colorimetric pyrophosphate release assays

Kinetic measurements:

• Steady-state kinetics to determine Km and kcat values for ATP, phenylalanine, and tRNAPhe

• Pre-steady-state kinetics using rapid quench or stopped-flow techniques to resolve individual reaction steps

Binding studies:

• Isothermal titration calorimetry to measure binding affinities for substrates

• Fluorescence spectroscopy to monitor conformational changes

• Thermal shift assays to assess protein stability and substrate binding

When designing these experiments, researchers should consider controls similar to those used for the related enzyme FARS2: "Functional analysis of the recombinant mutant p. Asp325Tyr FARS2 protein showed an inability to bind ATP and consequently undetectable aminoacylation activity using either bacterial tRNA or human mt-tRNA Phe as substrates" .

• How can researchers overcome the UGA codon usage issue when expressing M. pneumoniae genes?

Several strategies have proven successful for expressing M. pneumoniae proteins despite the UGA codon challenge:

Site-directed mutagenesis:

• Systematic replacement of UGA codons with UGG (standard tryptophan codon)

• Creation of synthetic genes with optimized codon usage for the expression host

Specialized expression systems:

• E. coli strains engineered to contain suppressor tRNAs for UGA recognition

• Cell-free protein synthesis systems supplemented with tRNATrp that recognizes UGA

Segmental expression:

• Expression of protein fragments to avoid regions containing UGA codons, as demonstrated with the M. pneumoniae P1 protein: "In the present study, we successfully expressed the C-terminal (P1-C1) and N-terminal (P1-N1) regions of the P1 protein in E. coli"

Expression protocol optimization:

• Adjusting induction conditions, temperature, and duration

• Co-expression with molecular chaperones to aid protein folding

These approaches have enabled successful expression of M. pneumoniae proteins that were previously recalcitrant to heterologous expression, opening new avenues for structural and functional studies.

• What structural approaches are most suitable for studying M. pneumoniae pheS in complex with its substrates?

Based on successful structural studies of related aminoacyl-tRNA synthetases, the following approaches are recommended:

X-ray crystallography:

• Particularly effective for obtaining high-resolution structures of pheS in complex with substrates or inhibitors

• Requires purification to near homogeneity (>95% purity) and screening of crystallization conditions

• Can reveal detailed active site architecture, as demonstrated for M. tuberculosis FRS: "High-resolution models reveal details of two modes of tRNA interaction with the enzyme: an initial recognition via indirect readout of anticodon stem-loop and aminoacylation ready state"

Cryo-electron microscopy:

• Increasingly valuable for studying larger complexes (e.g., full PheRS tetramer with tRNA)

• Doesn't require crystallization, potentially advantageous for conformationally flexible proteins

• May reveal different functional states in a single sample

Small-angle X-ray scattering (SAXS):

Computational approaches:

• Homology modeling based on related structures

• Molecular dynamics simulations to study conformational changes during catalysis

For mechanistic insights, researchers should consider co-crystallization with substrate analogs such as non-hydrolyzable ATP analogs or aminoacyl-adenylate mimics like F-AMS (5′-O-(N-phenylalanyl)sulfamoyl-adenosine) .

• How might M. pneumoniae pheS contribute to pathogenesis and represent a potential therapeutic target?

As an essential enzyme for protein synthesis, pheS represents both a potential virulence factor and therapeutic target, though direct evidence from the search results is limited.

Potential roles in pathogenesis:

• Essential for bacterial protein synthesis during infection and colonization of respiratory tract

• May contribute to persistent infection through its role in bacterial survival

• Could potentially be involved in antigenic variation mechanisms similar to those observed with M. pneumoniae adhesin proteins that utilize RepMP elements for sequence variation

Therapeutic targeting considerations:

• Structural differences between bacterial and human phenylalanyl-tRNA synthetases can be exploited for selective inhibition

• The active site architecture provides opportunities for structure-based drug design

• Insights from related enzymes suggest: "The presented topography of amino adenylate-binding and editing sites at different stages of tRNA binding to the enzyme provide insights for the rational design of anti-tuberculosis drugs"

Potential inhibition strategies:

• Adenylate analogs that compete with ATP or phenylalanyl-adenylate

• Compounds that disrupt tRNA binding

• Allosteric inhibitors that prevent conformational changes required for catalysis

Given that M. pneumoniae infections are typically seen in school-going children older than five years and young adults , with outbreaks occurring in crowded settings, selective inhibitors of pheS could represent valuable therapeutic agents for managing these infections.

• How do genetic variations in M. pneumoniae pheS compare across clinical isolates, and what are their functional implications?

While the search results don't specifically address variations in pheS genes across M. pneumoniae isolates, insights can be drawn from the organism's known genomic characteristics:

Genetic variation patterns:

• M. pneumoniae has a notably small genome with limited genetic diversity

• The organism does contain repetitive elements (RepMPs) that facilitate genomic rearrangements and antigenic variation

• Clinical isolates of M. pneumoniae fall into two major genetic types based on sequence variations: "Based on sequence divergence, M. pneumoniae strains belong to one of two groups; reference strain M129 is a representative of type 1, and strain FH is representative of type 2"

Methods for studying genetic variation in pheS:

• PCR amplification and sequencing of the pheS gene from clinical isolates

• Comparative genomic analysis across strain collections

• Expression and functional characterization of variant pheS proteins

Functional implications:

• Mutations affecting substrate binding sites could alter enzyme kinetics

• Variations at subunit interfaces might impact quaternary structure stability

• Changes in regulatory regions could affect expression levels

A comprehensive analysis would require:

• PCR amplification of pheS from diverse clinical isolates using methods similar to those used for P1 gene typing

• Sequence analysis to identify polymorphisms

• Recombinant expression of variant proteins

• Enzymatic characterization to assess functional consequences

• What is the interplay between M. pneumoniae pheS and the host immune system during infection?

While direct evidence about pheS-immune system interactions is not presented in the search results, important considerations include:

Potential immunological interactions:

• As an essential bacterial protein, pheS could potentially be recognized by the host immune system

• Antibodies against pheS might develop during infection, though their protective role is uncertain

• M. pneumoniae proteins can interact with host immune cells, as demonstrated by the DUF16 protein which "can enter macrophages and induce macrophage inflammatory response through the NOD2/RIP2/NF-κB pathway"

Research methodologies to explore this question:

• Serological studies to determine if anti-pheS antibodies are produced during natural infection

• Cell culture models to assess if pheS is recognized by pattern recognition receptors

• Animal models to evaluate immune responses to recombinant pheS

• Cytokine profiling following exposure of immune cells to purified pheS

Broader context:

• M. pneumoniae causes a range of respiratory illnesses from mild upper respiratory infections to pneumonia

• The organism can persist despite immune responses, suggesting immune evasion mechanisms

• Understanding the immunogenicity of essential proteins like pheS could inform vaccine development approaches

• What biochemical and biophysical techniques are most informative for characterizing inhibitors of M. pneumoniae pheS?

For researchers developing pheS inhibitors, several complementary techniques provide valuable information:

Enzyme inhibition assays:

Binding studies:

• Isothermal titration calorimetry to measure binding constants and thermodynamic parameters

• Surface plasmon resonance for real-time binding kinetics

• Fluorescence-based thermal shift assays to measure stabilization upon inhibitor binding

Structural characterization:

• X-ray crystallography of enzyme-inhibitor complexes

• NMR studies for mapping binding interfaces

• Hydrogen-deuterium exchange mass spectrometry to detect conformational changes

Examples from related research:
The adenylate analog F-AMS (5′-O-(N-phenylalanyl)sulfamoyl-adenosine) has been demonstrated as an effective inhibitor of related Phe-tRNA synthetases: "We biochemically validated the inhibitory potency of the adenylate analog and provide the most complete view of the Phe-tRNA synthetase/tRNA Phe system to date" .

Design considerations:

• Mimicry of reaction intermediates (e.g., phenylalanyl-adenylate)

• Exploitation of species-specific active site features

• Optimization of pharmacokinetic properties for respiratory tract infections

• How can recombinant M. pneumoniae pheS be used in diagnostic applications for M. pneumoniae infections?

While current diagnostic approaches for M. pneumoniae focus on other proteins (particularly adhesins) , recombinant pheS could potentially contribute to improved diagnostics:

Potential diagnostic applications:

• As an antigen in serological assays to detect anti-pheS antibodies in patient samples

• For generation of high-quality antibodies to detect M. pneumoniae in clinical specimens

• As a positive control in molecular diagnostic assays

Development methodology:

• Expression and purification of recombinant pheS using approaches discussed in question 3

• Validation of immunogenicity and specificity using techniques similar to those described for the P1 protein: "On screening these recombinant proteins with sera from M. pneumoniae-infected patients, only the P1-C1 protein was found to be immunogenic"

• Evaluation in clinical samples using standardized protocols

Evaluation in clinical context:

• Correlation with established diagnostic methods

• Assessment of sensitivity and specificity across different patient populations

• Comparison with current diagnostic approaches like real-time PCR used to detect Mycoplasma pneumoniae

Current M. pneumoniae diagnostics include culture, serology, and molecular methods , and any new diagnostic application would need to demonstrate advantages over these established techniques in terms of sensitivity, specificity, or ease of use.